Drug intelligence / Profile preview

CYB006

Development stage: Preclinical
Lead developer: Cybin
Modality: Small Molecules

Overview

CYB006 is a proprietary psychedelic molecule developed by Cybin, stemming from its acquisition of Adelia Therapeutics. It is part of Cybin's pipeline of novel psychedelic compounds, which are designed with chemical modifications, such as deuteration, to potentially improve their properties compared to naturally occurring psychedelic molecules. CYB006 is currently in the research phase, undergoing preclinical evaluation for its potential in treating mental health disorders.

Targets

HTR2A (Serotonin receptor 5-HT2A)MAT (Monoamine transporters)

Beyond the preview

Go deeper on CYB006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYB006.

Explore the full profile